Millis R R, Springall R, Lee A H S, Ryder K, Rytina E R C, Fentiman I S
Hedley Atkins ICRF Breast Pathology Laboratory, Guy's Hospital, London SE1 9RT, UK.
Br J Cancer. 2002 Feb 1;86(3):396-401. doi: 10.1038/sj.bjc.6600070.
The significance of occult metastases in axillary lymph nodes in patients with carcinoma of the breast is controversial. Additional sections were cut from the axillary lymph nodes of 477 women with invasive carcinoma of the breast, in whom no metastases were seen on initial assessment of haematoxylin and eosin stained sections of the nodes. One section was stained with haematoxylin and eosin, and one using immunohistochemistry with two anti-epithelial antibodies (CAM5.2 and HMFG2). Occult metastases were found in 60 patients (13%). The median follow-up was 18.9 years with 153 breast cancer related deaths. There was no difference in survival between those with and those without occult metastases. Multivariate analysis, however, showed that survival was related to tumour size and histological grade. This node-negative group was compared with a second group of 202 patients who had one involved axillary node found on initial assessment of the haematoxylin and eosin sections; survival was worse in the patients in whom a nodal metastasis was found at the time of surgery. Survival was not related to the size of nodal metastases in the occult metastases and single node positive groups. Some previous studies have found a worse prognosis associated with occult metastases on univariate analysis, but the evidence that it is an independent prognostic factor on multivariate analysis is weak. We believe that the current evidence does not support the routine use of serial sections or immunohistochemistry for the detection of occult metastases in the management of lymph node negative patients, but that the traditional factors of histological grade and tumour size are useful.
乳腺癌患者腋窝淋巴结隐匿性转移的意义存在争议。对477例浸润性乳腺癌女性患者的腋窝淋巴结进行了额外切片检查,这些患者在最初苏木精-伊红染色切片评估时未发现转移。其中一张切片进行苏木精-伊红染色,另一张采用免疫组织化学方法,使用两种抗上皮抗体(CAM5.2和HMFG2)。60例患者(13%)发现隐匿性转移。中位随访时间为18.9年,有153例与乳腺癌相关的死亡病例。有隐匿性转移和无隐匿性转移患者的生存率无差异。然而,多因素分析显示,生存率与肿瘤大小和组织学分级有关。将这组淋巴结阴性患者与另一组202例患者进行比较,后一组患者在最初苏木精-伊红切片评估时发现有一个腋窝淋巴结受累;手术时发现有淋巴结转移的患者生存率较差。隐匿性转移组和单个淋巴结阳性组的生存率与淋巴结转移大小无关。一些先前的研究在单因素分析中发现隐匿性转移与预后较差有关,但在多因素分析中其作为独立预后因素的证据不足。我们认为,目前的证据不支持在淋巴结阴性患者的管理中常规使用连续切片或免疫组织化学检测隐匿性转移,而组织学分级和肿瘤大小等传统因素是有用的。